title: Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse.
abstract: T-cell reconstitution after allo-SCT initially depends on homeostatic peripheral expansion of donor T cells, the level of which may promote the differentiation of alloreactive and tumor-reactive effectors. IL-7 and IL-15 exert their effect as key homeostatic cytokines. We prospectively investigated plasma levels of IL-7 and IL-15 in a homogeneous group of 40 patients in CR of their hematologic malignancy undergoing myeloablative, fully (10/10) HLA-matched BMT. IL-7 and IL-15 proceeded along similar kinetic courses, peaking at wide ranges (3.8-30.2 and 14.3-66 pg/ml, respectively) on day +14 when all patients were profoundly lymphopenic. Occurrence and grade of subsequent acute GVHD were significantly associated with heightened day +14 IL-7 and IL-15 levels. Association of peak IL-7 level to grade 2-4 acute GVHD was confirmed by Cox multivariate analysis (hazard ratio (HR)=5.38; P=0.022). Malignancy relapse was significantly associated with reduced day +14 levels of IL-15 (Cox multivariate analysis: HR=0.93; P=0.035). Plasma IL-7 and IL-15 levels in the early post transplantation period are therefore biomarkers that can help predict subsequent development of acute GVHD and malignancy relapse.
authors.affiliation: Universite Lille Nord de France, Lille, France.
authors.forename: S
authors.initials: S
authors.lastname: Thiant
authors.forename: I
authors.initials: I
authors.lastname: Yakoub-Agha
authors.forename: L
authors.initials: L
authors.lastname: Magro
authors.forename: J
authors.initials: J
authors.lastname: Trauet
authors.forename: V
authors.initials: V
authors.lastname: Coiteux
authors.forename: J-P
authors.initials: JP
authors.lastname: Jouet
authors.forename: J-P
authors.initials: JP
authors.lastname: Dessaint
authors.forename: M
authors.initials: M
authors.lastname: Labalette
mesh_terms: D000293:Adolescent; D000328:Adult; D015415:Biomarkers / Q000097:blood; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D042241:Early Diagnosis; D005260:Female; D006086:Graft vs Host Disease / Q000097:blood* / Q000175:diagnosis*; D019337:Hematologic Neoplasms / Q000628:therapy; D006648:Histocompatibility; D006801:Humans; D019409:Interleukin-15 / Q000097:blood*; D015851:Interleukin-7 / Q000097:blood*; D007700:Kinetics; D008231:Lymphopenia / Q000097:blood; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000175:diagnosis*; D012720:Severity of Illness Index; D019172:Transplantation Conditioning; D055815:Young Adult
chemical_list: D015415:Biomarkers; C508605:IL7 protein, human; D019409:Interleukin-15; D015851:Interleukin-7; D019653:Myeloablative Agonists